CEL-SCI (NYSEAMERICAN:CVM) Stock Price Down 5.5%

Shares of CEL-SCI Co. (NYSEAMERICAN:CVM) fell 5.5% on Friday . The company traded as low as $7.82 and last traded at $7.85, 541,100 shares changed hands during mid-day trading. A decline of 25% from the average session volume of 718,801 shares. The stock had previously closed at $8.31.

CEL-SCI (NYSEAMERICAN:CVM) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.27). The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.10 million.

In other news, SVP John Cipriano sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $8.69, for a total transaction of $69,520.00. Following the completion of the sale, the senior vice president now owns 83,108 shares in the company, valued at $722,208.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of CEL-SCI during the second quarter valued at approximately $25,000. Captrust Financial Advisors purchased a new position in shares of CEL-SCI during the second quarter valued at approximately $25,000. Endurance Wealth Management Inc. purchased a new position in shares of CEL-SCI during the second quarter valued at approximately $29,000. JPMorgan Chase & Co. purchased a new position in shares of CEL-SCI during the second quarter valued at approximately $57,000. Finally, Morgan Stanley boosted its position in shares of CEL-SCI by 12.0% during the second quarter. Morgan Stanley now owns 27,255 shares of the company’s stock valued at $228,000 after buying an additional 2,916 shares during the last quarter.

About CEL-SCI (NYSEAMERICAN:CVM)

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Further Reading: What is the NASDAQ Stock Market?

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.